Home›The Library›BPC-157 vs TB-500
BPC-157 vs TB-500
The two most commonly stacked "healing peptides" — sold together constantly, marketed almost identically. Neither has a completed human efficacy trial. The real difference between them is subtler and more specific than that: BPC-157 now has a handful of tiny uncontrolled human pilot studies; the molecule actually sold as "TB-500" has none of its own at all.
On this page
In brief
Should you care? Yes, if you've seen these two marketed as a matched pair — they're not evidenced the same way, even though their legal status has moved in lockstep. BPC-157 has a few small human pilot studies now; "TB-500" as sold has zero of its own.The short version
- BPC-157: almost entirely rodent evidence, plus three small, uncontrolled 2024–2025 human pilot studies (interstitial cystitis, knee pain, IV safety) — no placebo-controlled efficacy trial.
- "TB-500": the human trial data cited for it was run on a different, larger molecule (full-length thymosin beta-4) — the actual fragment sold under that name has never been tested in a human trial of any kind.
- Legal status: both removed from FDA Category 2 in April 2026, and both recommended — not yet finalized — for compounding eligibility by the same July 2026 advisory committee vote.
Side by side
| BPC-157 | TB-500 (as sold) | |
|---|---|---|
| What it is | Synthetic 15-amino-acid peptide, derived from a fragment of a gastric-juice protein | Synthetic 7-amino-acid fragment (Ac-LKKTETQ) of thymosin beta-4, a different, larger protein |
| Marketed for | Tendon/ligament/gut healing, joint pain | Wound healing, flexibility, tissue repair |
| Animal evidence | Extensive rodent studies (gut, tendon, ligament, wound models) | Peer-reviewed rat wound-healing data — for full-length Tβ4, not the fragment sold as "TB-500" |
| Human evidence | 3 small uncontrolled pilot studies (2024–2025): interstitial cystitis (n=12), knee pain (n=16), IV safety (n=2) | None of its own. A 2009 company-reported Phase 2 result exists only for full-length Tβ4 (RGN-137 gel), a different molecule. |
| Placebo-controlled efficacy trial | None published | None published (for either molecule) |
| FDA Category 2 removal | April 2026 (12-peptide removal) | April 2026 (same 12-peptide removal) |
| July 2026 PCAC vote | Recommended, 8-6, one abstention | Recommended, 8-6, one abstention (same day) |
| Category 1 status | Not yet finalized | Not yet finalized |
Why they get stacked together
BPC-157 and TB-500 are sold together constantly, usually as a single "healing stack," on the logic that one works on soft tissue directly (BPC-157's proposed mechanism runs through angiogenesis and nitric-oxide signalling) while the other works through cell migration and actin regulation (thymosin beta-4's proposed mechanism). See each compound's own BPC-157 and TB-500 page for the full evidence and legal-status detail. That two-mechanism pitch is a real biological rationale — it is not, on its own, evidence that either compound works in a person, let alone that combining them adds anything.
The human-evidence gap, and it's not the same gap
It's tempting to lump these two together as "equally unproven," and for efficacy that's fair — neither has a completed, published, placebo-controlled human trial for anything it's actually sold for. But the size and shape of the evidence gap genuinely differs. BPC-157 has picked up a small amount of real, if very limited, human data since 2024: a narrative review (McGuire et al., Curr Rev Musculoskelet Med, published online 12 August 2025, DOI 10.1007/s12178-025-09990-7) catalogues three published human pilot studies — a 12-patient uncontrolled interstitial-cystitis study reporting symptom improvement in 10 of 12 patients (Lee, Walker & Ayadi, Altern Ther Health Med 2024;30(10):12-17, PMID 39325560), a 16-patient uncontrolled intra-articular knee-pain study, and a 2-subject intravenous safety pilot finding no adverse effects up to 20mg (Lee & Burgess, Altern Ther Health Med 2025). All three are small, uncontrolled, and none is a randomized efficacy trial — the review's own conclusion is that BPC-157 remains investigational and should be approached with caution — but they are real, published, human data that didn't exist a few years ago.
"TB-500" has none of that. The synthetic 7-amino-acid fragment actually sold under that name has never appeared in a published human study of its own, at any size, controlled or not. Every human data point anyone cites for "TB-500" — including the 2009 RegeneRx result — was actually generated using full-length thymosin beta-4, a chemically distinct, roughly six-times-larger molecule. See TB-500's own page for the full molecular-weight comparison and why that distinction matters. A buyer choosing between the two is not choosing between two equally-untested compounds; one has a thin trail of small human pilot data pointing at the actual molecule in the vial, and the other has zero.
"Some human data" is not the same as "it works"
Three uncontrolled pilot studies with a combined 30 human subjects, none placebo-controlled, is a genuinely thin evidence base — not remotely comparable to an approved-drug trial program. The comparison here is BPC-157 versus TB-500, not BPC-157 versus proof.
Legal status: identical, and identically unfinished
Unusually for two different compounds, their regulatory timelines have moved in exact lockstep. Both were among the 12 peptides FDA removed from Category 2 in April 2026, and both went before the same Pharmacy Compounding Advisory Committee meeting on 23–24 July 2026, where both were recommended for the Section 503A bulks list by the same 8-6, one-abstention vote on the same day — despite FDA's own staff having recommended against inclusion for the group beforehand. See BPC-157's legal status and TB-500's legal status pages for what that process means in full. A PCAC recommendation is advisory only; as of this page's last review, neither compound has been placed in Category 1 through the FDA's own further rulemaking step, and neither is an approved drug or a lawful dietary-supplement ingredient.
The honest bottom line
If a vendor is selling these as an interchangeable pair — same legal status, same "almost legal" framing, same lack of proof — the legal-status half of that pitch is accurate: they really have moved together. The evidence half is not. BPC-157 has a small but real and growing human pilot record; the peptide actually sold as "TB-500" does not, and never has. Neither difference changes the bottom line that both remain unapproved, injectable, self-administered substances with no completed efficacy trial in a real patient population — but if you're being asked to trust one molecule's human safety data more than the other's, BPC-157 currently has more of it, however thin.
References
- McGuire, Martinez, Lenz, Skinner & Cushman, "Regeneration or Risk? A Narrative Review of BPC-157 for Musculoskeletal Healing," Curr Rev Musculoskelet Med, published online 12 August 2025, DOI 10.1007/s12178-025-09990-7, PMID 40789979 — cataloguing all published human pilot data on BPC-157 as of 2025 and concluding it remains investigational.
- Lee, Walker & Ayadi, "Effect of BPC-157 on Symptoms in Patients with Interstitial Cystitis: A Pilot Study," Altern Ther Health Med 2024;30(10):12-17, PMID 39325560 — 12 women, uncontrolled, single-arm.
- Lee & Burgess, "Safety of Intravenous Infusion of BPC-157 in Humans: A Pilot Study," Altern Ther Health Med 2025 — 2 healthy adults, escalating IV doses to 20mg, no placebo arm.
- RegeneRx Biopharmaceuticals, Phase II venous stasis ulcer trial results announcement, 26 March 2009 (full-length thymosin beta-4, not the fragment sold as "TB-500"); see the TB-500 page for the full molecular distinction and citation.
- FDA, Pharmacy Compounding Advisory Committee meeting, 23–24 July 2026; both BPC-157 and TB-500 recommended for the Section 503A bulks list, 8-6 with one abstention, 23 July. See the BPC-157 and TB-500 pages for the fully-cited independent corroboration of this vote.